Latest News for: tki

Edit

123Invent Inventor Develops Improved Hardware Item (TKI-1270)

PR Newswire 22 Dec 2025
PITTSBURGH , Dec ... My design would offer a more effective and affordable option than traditional mounts and hardware items.". The invention provides an improved hardware item for mounting or attaching items to a wall ... SOURCE InventHelp. 21% ... .
Edit

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma (Glenmark Pharmaceuticals Limited)

Public Technologies 16 Dec 2025
) Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma ... China-developed EGFR-TKI to be launched internationally.
Edit

123Invent Inventor Develops New Accessory for Sports Fans (TKI-1261)

PR Newswire 02 Dec 2025
PITTSBURGH, Dec ... My design can be easily applied onto the nose to show that a call, play, or team stinks.". The invention provides a new accessory for sports enthusiasts ... SOURCE InventHelp. 21%. more press release views with. Request a Demo. .
Edit

DeltaV’den Yerli Ramjet İtki Sistemi Test Başarısı

Istiklal 23 Nov 2025
Tarafsız ve güvenilir habercilik için tıklayın ....
Edit

Final Overall Survival Analysis : HARMONi-A Study Ivonescimab + chemotherapy versus Chemotherapy In patients with EGFR-mutant NSCLC progressed on EGFR TKI (Summit Therapeutics Inc)

Public Technologies 21 Nov 2025
EGFR-mutant NSCLC progressed on EGFR TKI ... EGFR, epidernal growth factor receptor; TKI, tyrosine-kinase inhibitor; ICI, innune checkpoint inhibitor; PD-1, progranned death-1; PD-L1, progranned death ligand 1; PFS, progression-free survival.
Edit

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI ...

Citizen Tribune 19 Nov 2025
NDA based on data from global ARROS-1 Phase 1/2 clinical trial ....
Edit

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

PR Newswire 19 Nov 2025
... kinase inhibitor (TKI) ... The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI-naïve and TKI pre-treated patients with advanced ROS1-positive NSCLC.
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated ...

Citizen Tribune 17 Nov 2025
In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI. 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectivelyIn the subset of 63 TKI pre-treated patients who ....
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

PR Newswire 17 Nov 2025
In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI ... Efficacy Analysis in TKI Pre-treated Advanced ALK-positive NSCLC ... Of the overall TKI pre-treated population, 25% (63/253) of patients were lorlatinib-naïve ... TKI Pre-treated,.
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC (Nuvalent Inc)

Public Technologies 17 Nov 2025
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI ... Any prior ALK TKI.
Edit

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC ...

The Galveston Daily News 14 Nov 2025
Company to host webcast and conference call on November 17, 2025 at 8.00am ET ....
Edit

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

PR Newswire 14 Nov 2025
ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.
Edit

First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab ...

The Ridgway Record 31 Oct 2025
HONG KONG, Oct.
Edit

First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025

PR Newswire 30 Oct 2025
Final Overall Survival Analysis of HARMONi-A Study Comparing Ivonescimab Plus Chemotherapy to Chemotherapy Alone in Patients With EGFR+ NSCLC Progressed on EGFR-TKI Treatment Abstract Number.
Edit

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

PR Newswire 20 Oct 2025
... (TKI) therapy ... Consistent PFS and OS benefits were observed across all prespecified subgroups, including prior EGFR-TKI therapy, presence of liver or brain metastases, and EGFR mutation subtype.

Article Search

tools
×
×
×
×